Welcome to our dedicated page for Kalvista Pharm news (Ticker: KALV), a resource for investors and traders seeking the latest updates and insights on Kalvista Pharm stock.
KalVista Pharmaceuticals develops and commercializes oral small-molecule therapies for rare diseases, with a focus on the kallikrein-kinin system. Its FDA-approved product EKTERLY (sebetralstat) is an oral plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema, and company updates often center on launch activity, product revenue, and use of oral on-demand therapy in HAE.
KalVista news also covers clinical and scientific updates for sebetralstat, including pediatric HAE work through the KONFIDENT-KID trial, medical-conference presentations, financial results, inducement equity grants, governance matters, capital-structure disclosures, and material agreements.
KalVista (Nasdaq: KALV) reported new clinical data showing high patient satisfaction and shifting treatment behavior with oral EKTERLY (sebetralstat). In KONFIDENT-S, patients treated 2,464 attacks with sebetralstat; 83.1% of treated attacks rated satisfied or better and use of injectables fell with repeated use.
Analyses showed treating within 30 minutes predicted faster symptom relief, with simulations suggesting nearly 90% might experience relief within 12 hours.
KalVista Pharmaceuticals (Nasdaq: KALV) will present fireside chats at two investor conferences in March 2026. The company will speak at TD Cowen on March 4, 2026 at 11:10 a.m. EST and at Citizens Life Sciences on March 11, 2026 at 10:45 a.m. EST.
According to the company, live audio webcasts will be available on the Investors section of its website, with archived replays posted about two hours after each event.
KalVista (Nasdaq: KALV) said the new International Pediatric HAE Guideline recommends EKTERLY (sebetralstat) as a first-line on-demand therapy for acute hereditary angioedema attacks in adolescents aged 12 and older.
The guideline cites robust clinical evidence, notes EKTERLY is the first oral on-demand option for 12+, follows seven global approvals in 2025, and highlights ongoing pediatric development with an NDA for ages 2–11 on track for Q3 2026.
KalVista Pharmaceuticals (Nasdaq: KALV) announced the acceptance of three abstracts for presentation at the 2026 AAAAI Annual Meeting in Philadelphia, Feb 27–Mar 2, 2026. Two poster sessions are scheduled Friday, Feb 27 (2:45–3:45 pm ET) and one late-breaking poster on Sunday, Mar 1 (9:45–10:45 am ET).
Titles include placebo‑controlled response drivers, on‑demand treatment patterns from KONFIDENT‑S, and an investigator‑initiated ECRINS survey on attack management and burden. Links to presentations will be available on the company website under Publications.
KalVista Pharmaceuticals (Nasdaq: KALV) announced inducement option grants to six newly hired employees totaling 96,750 shares on February 1, 2026. Options vest 25% after one year, then monthly over three years, have a 10-year term, and an exercise price equal to the first reported closing price after the grant date.
Grants were made under KalVista’s Inducement Equity Incentive Plan and in accordance with Nasdaq Listing Rule 5635(c)(4).
KalVista (Nasdaq: KALV) reported preliminary unaudited global net product revenue for its oral on-demand HAE therapy EKTERLY (sebetralstat) of approximately $35 million in Q4 2025 and $49 million for full-year 2025 following a July 7 US launch.
Operational traction includes 1,318 patient start forms and 580 activated US prescribers through December 31, 2025, strong early uptake in Germany, regulatory approvals in seven markets, a new Latin America licensing deal with Multicare, and completion of Phase 3 KONFIDENT-KID pediatric enrollment with an expected pediatric NDA filing in Q3 2026.
KalVista Pharmaceuticals (Nasdaq: KALV) announced that Japan's Ministry of Health, Labor and Welfare granted marketing and manufacturing approval for EKTERLY (sebetralstat) as an oral on-demand treatment for acute hereditary angioedema (HAE) attacks in adults and adolescents aged 12 and older.
EKTERLY is the first and only oral on-demand HAE treatment approved in Japan and will be commercialized in Japan by partner Kaken Pharmaceutical, which plans to launch after EKTERLY is listed on the Japanese National Health Insurance system. Approval relied on the phase 3 KONFIDENT trial—the largest HAE study (136 patients, 66 sites, 20 countries)—with results published in the New England Journal of Medicine showing faster symptom relief, reduced attack severity, and attack resolution versus placebo. Since July 3, 2025, EKTERLY has received seven regulatory approvals across major markets.
KalVista Pharmaceuticals (Nasdaq: KALV) reported third-quarter 2025 results and an operational update focused on the commercial launch of EKTERLY. The company recognized $13.7M in net product revenue for Q3 and received 937 patient start forms through October with 423 unique prescribers activated. EKTERLY launched in Germany and received approvals in the EU, Switzerland and Australia. KalVista closed a $144M convertible note and held $309.2M in cash and marketable securities as of September 30, 2025.
R&D declined to $12.0M and SG&A rose to $46.5M in Q3 2025, reflecting commercialization activity.
KalVista (Nasdaq: KALV) presented new patient satisfaction and pediatric data for EKTERLY (sebetralstat) at ACAAI 2025 on November 6, 2025.
Key findings: in KONFIDENT-S, 1,089 attacks treated by patients who switched from injectable on-demand therapies had a median satisfaction score of 2 on a −3 to 3 Likert scale, with 84% of attacks rated satisfied/very/extremely satisfied. Interim KONFIDENT-KID results (as of June 6, 2025) in 26 children covering 65 attacks showed mean 0.8 attacks/month, median treatment administration time by caregiver/patient 30 minutes, median time to symptom relief in the 150 mg cohort 1.5 hours, and no serious or treatment-related adverse events reported.
Complementary Delphi and survey data highlighted barriers to injectable care (86% delay rate) and strong patient preference for oral on-demand treatment (89%).
KalVista Pharmaceuticals (Nasdaq: KALV) will participate in fireside chats at two investor conferences in November 2025.
Events and times: Stifel 2025 Healthcare Conference on Wednesday, November 12, 2025 at 8:40 a.m. EST, and Jefferies Global Healthcare Conference (London) on Wednesday, November 19, 2025 at 1:30 p.m. GMT.
Live audio webcasts will be available on the company Investors page at www.ir.kalvista.com/event-calendar, with archived replays posted approximately two hours after each event concludes.